Gastrointestinal stromal tumors (GISTs) have distinct gene expression patterns according to localization, genotype and aggressiveness. DNA methylation at CpG dinucleotides is an important mechanism for regulation of gene expression. We performed targeted DNA methylation analysis of 1.505 CpG loci in 807 cancer-related genes in a cohort of 76 GISTs, combined with genome-wide mRNA expression analysis in 22 GISTs, to identify signatures associated with clinicopathological parameters and prognosis. Principal component analysis revealed distinct DNA methylation patterns associated with anatomical localization, genotype, mitotic counts and clinical follow-up. Methylation of a single CpG dinucleotide in the non-CpG island promoter of SPP1 was significantly correlated with shorter disease-free survival. Hypomethylation of this CpG was an independent prognostic parameter in a multivariate analysis compared to anatomical localization, genotype, tumor size and mitotic counts in a cohort of 141 GISTs with clinical follow-up. The epigenetic regulation of SPP1 was confirmed in vitro, and the functional impact of SPP1 protein on tumorigenesis-related signaling pathways was demonstrated. In summary, SPP1 promoter methylation is a novel and independent prognostic parameter in GISTs, and might be helpful in estimating the aggressiveness of GISTs from the intermediate-risk category.
15% of GISTs, respectively. 1, 2 The histomorphologic appearance and clinical behavior are significantly different between gastric and small intestinal GISTs, 3, 4 and also between GISTs with KIT and PDGFRA mutations. 5, 6 Gastric GISTs and GISTs with PDGFRA mutations are associated with less aggressive behavior compared to small intestinal GISTs and to GISTs with KIT mutations. [3] [4] [5] [6] Array-based genome-wide expression studies have shown significant differences in mRNA expression signatures comparing gastric and small intestinal GISTs, 7, 8 GISTs with KIT and PDGFRA mutations 9, 10 and according to risk classification. 8, 11 However, little is known about the underlying mechanisms regulating these expression signatures.
Epigenetic regulation by DNA methylation of cytosine residues in CpG dinucleotides silences gene expression by affecting the recruitment of regulatory proteins to DNA, 12 and has been shown to play causal roles in the pathogenesis of several cancers. 13 However, only limited data have been reported concerning epigenetic mechanisms in GIST tumorigenesis and prognosis.
14 Two earlier studies have reported downregulation of the CDK inhibitor p16 INK4A , partly due to promoter hypermethylation of the corresponding gene locus CDKN2A, as a prognostic marker for GIST progression. 15, 16 Hypomethylation of LINE-1 repeats was found to correlate with risk classification and chromosomal instability. 17 Another study has compared the global DNA methylation patterns in GISTs of different risk categories, and identified REC8 and PAX3 to be differentially methylated in small vs. malignant GISTs. 18 Epigenetic silencing of the tumor suppressor gene PTEN has been found after long-term exposure of GIST tumor cells to sunitinib. 19 In our study, we performed targeted DNA methylation profiling in a large cohort of primary GISTs and observed distinct methylation patterns according to anatomical localization, genotype and mitotic counts. According to the prognostic value of these factors, we established a linear model to identify DNA methylation events that are associated with tumor progression independently of the classical clinicopathological parameters mentioned above. On the basis of correlation analysis with gene expression and in vitro findings, we demonstrate methylation of Secreted Phosphoprotein 1 (SPP1) promoter as a potent regulator of its expression, and highlight SPP1 promoter hypomethylation as a novel and independent prognostic parameter in GISTs.
Material and Methods

Tumor samples
A cohort of 76 fresh-frozen tumor samples from primary GISTs without previous imatinib treatment was used for targeted DNA methylation analysis (test set). An additional cohort of 99 paraffin-embedded imatinib-na€ ıve primary GISTs was used as the validation set. Clinical follow-up was available for 42 of the 76 fresh-frozen GISTs of the test set, and for all 99 paraffin-embedded GISTs of the validation set. For each tumor, DNA was isolated from fresh-frozen or paraffin-embedded tissue using the Qiagen Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's manual, and DNA concentration was quantified with a NanoDrop 1000 (Thermo Scientific, Wilmington, DE). Mutation analysis of KIT exons 9, 11, 13 and 17 as well as PDGFRA exons 12, 14 and 18 was performed in all 175 samples using the methods previously described. 20 This study was approved by the ethics committee of the University of G€ ottingen (No. 8/9/07).
DNA methylation analysis
The 76 GISTs from the test set were analyzed with the Golden Gate Methylation Cancer Panel I (Illumina, San Diego, CA) at 1,505 CpG loci associated with 807 cancer-related genes. DNA methylation patterns of six individual CpG loci in the promoter region of SPP1 were evaluated by bisulfite sequencing in DNA samples from three GISTs with varying levels of SPP1 methylation according to the Golden Gate Methylation data set. After sodium bisulfite treatment using the EpiTect bisulfite Kit (Qiagen), a genomic region upstream of the transcription start site of SPP1 was amplified by polymerase chain reaction (PCR) using the following primers: SPP1_SBF1 AATGTGTAAAATTTTTTTATTGATGTA-TAT and SPP1_SBR1 ATCCTTTACTACTCAAACTTAACTT-TATAA. PCR products were cloned using the TOPO TA cloning kit for sequencing (Invitrogen, Carlsbad, CA), and ten individual clones from each sample were sequenced. Bisulfite pyrosequencing of the most informative SPP1 CpG site (SPP1_P647_F) was performed for all samples. A 73-bp fragment of the SPP1 promoter region was PCR-amplified from bisulfite-treated DNA (EZ DNA Methylation-Gold Kit; Zymo Research, Irvine, CA) using GTATTTTATGGATGAGGGAATAAGGATAG (forward) and ATCACTACTAACCTATACAACCTTAAAC (reverse) primers. Pyrosequencing reactions were done using the PyroMark Gold Q24 Reagents (Qiagen) in a PyroMark Q24 Pyrosequencing System (Qiagen) with the pyrosequencing primer
What's new?
Variations in the clinical behavior of gastrointestinal stromal tumors (GISTs) are associated with underlying variations in gene expression. But the mechanisms regulating gene expression in GIST and how they influence tumor progression remain unclear. A mechanism implicated in the present study is epigenetic dysregulation, specifically of secreted phosphoprotein 1 (SPP1), based on targeted DNA methylation profiling and genome-wide mRNA expression analysis in a cohort of GISTs. In vitro experiments indicate that SPP1 raises oncogenic potential by influencing the activation of major intracellular regulators. The findings suggest that SPP1 hypermethylation is an independent prognostic marker in GIST.
AGGGAATAAGGATAGGTA. Quantification of CpG methylation was performed using the Software PyroMark 24 v.2.0.6 (Qiagen), with correction for minor bias toward unmethylated alleles as previously described. 21 mRNA expression analysis In vitro inhibition of DNA methylation and SPP1 stimulation in GIST cell lines Cell culture conditions for GIST cell line GIST882 were as described previously. 22 Cells were cultured for 24 hr and then treated with 10 or 25 nM concentrations of 5-aza-2 0 -deoxycytidine (A3656-5MG, Sigma-Aldrich Chemie GmbH, Munich, Germany) for 72 hr. After treatment, DNA and total RNA were isolated for DNA methylation analysis using pyrosequencing and for mRNA expression analysis using qRT-PCR as described above. Additionally, protein lysates were collected, and Western blot analysis of SPP1 protein levels was performed using a monoclonal anti-SPP1 antibody (LFMb-14, Santa Cruz Biotechnology, Santa Cruz, CA). To examine downstream signaling of SPP1, GIST882 cells were treated with 1 mg recombinant SPP1 after starvation of the cells, and cell lysis was done on ice at different time points (0, 5, 15, 30 and 60 min). Western blot analyses for expression as well as phosphorylation of AKT and ERK1/2 were carried out as described previously. 23 
Statistical analysis
Read-outs from Golden Gate Methylation Cancer Panel I were normalized with logit-transformation. Principal components analysis was performed with the ROBPCA algorithm. 24 Differential methylation was detected by establishing a linear model with classical clinical parameters as covariates and by moderated t-tests followed by Benjamini & Hochberg adjustment to control false-discovery rate (FDR) under 0.01, as described by the Bioconductor package limma. 25 Briefly, for each CpG locus, the logit-transformed methylation value y was fitted to the following model:
where m represents the baseline methylation level, l, g, m and p present factor variables of anatomical localization, genotype, mitotic counts and tumor progression, respectively, and bs represent respective coefficients. By this model, we assume that the methylation status of each CpG locus can be explained by the linear combination of four factors. The linear model was fitted and null hypotheses were tested assuming that the coefficients (bs) equal zero. Benjamini-Hochberg multiple-testing adjustment was performed. All statistical tests were performed with R and Bioconductor, 26 or with SPSS Statistics software (IBM, New York, NY).
Results
Unsupervised targeted DNA methylation analysis classifies GISTs into subgroups correlated to anatomical localization and genotype
A three-dimensional principal component analysis (PCA) was performed to detect distinct patterns in 76 fresh-frozen GIST samples according to the methylation status of 1,505 CpG loci representing 807 cancer-related genes (Fig. 1a) . Correlation with clinicopathological parameters revealed that the GISTs separated into three distinct groups: gastric with KIT mutation; small intestine with KIT mutation and gastric with PDGFRA mutation. Two rectal GISTs with KIT mutation clustered with the gastric KIT-mutated GISTs, while three wild-type GISTs clustered according to their anatomical localization (either gastric or small intestinal) among the KIT-mutated GISTs. Interestingly, one CpG locus located in the promoter region of the gene prominin 1 (PROM1)/CD133 as well as two CpG loci located in the promoter region of the gene CD34 molecule (CD34) displayed a similar methylation pattern, with low methylation levels in KIT-mutated GISTs from the stomach and rectum, in contrast to high methylation levels in KIT-mutated GISTs from the small intestine ( Fig. 1 and Table 1 ).
The methylation status of distinct CpG loci is associated with anatomical localization, genotype, mitotic counts and tumor progression in GIST The standard prognostication of clinical behavior in GIST is based on the parameters anatomical localization, size and mitotic counts. Accordingly, novel and additional molecular parameters have to be of independent prognostic value compared to those well-established and easily accessible factors. Thus, we used a linear model to identify CpG loci that give additional prognostic information beyond those classical Cancer Cell Biology Figure 1 . Targeted DNA methylation analysis identified SPP1 as a novel prognostic factor. (a) Unsupervised three-dimensional PCA reveals distinct patterns of DNA methylation in relation to anatomical localization and genotype. There is a clear separation of three distinct groups: KIT-mutated GISTs from the stomach (green), KIT-mutated GISTs from the small intestine (blue) and PDGFRA-mutated GISTs from the stomach (purple). Rectal GISTs (black) cluster with gastric KIT-mutated GISTs, and wild-type GISTs (orange) cluster according to their anatomical localization within the KIT-mutated tumors. (b) Heatmap of differentially methylated CpG loci according to clinicopathological parameters and tumor progression. The linear model revealed a significant association of DNA methylation at specific CpG loci with anatomical localization (25 CpG loci), genotype (three CpG loci), mitotic counts (21 CpG loci) and tumor progression (two CpG loci). Three CpG loci located in the promoter regions of PROM1/CD133 and CD34 display a similar methylation pattern within GIST from different sites of the gastrointestinal tract. The linear model further demonstrates that hypomethylation of the CpG locus SPP1_P647_F in the promoter region of SPP1 is independently correlated to tumor progression. Sm. i.: small intestinal; rec.: rectal; non p.: nonprogressive; p.: progressive; n.a.: not available. (c) Correlation analysis of DNA methylation (y-axis) and genome-wide mRNA expression (x-axis) was used to detect 31 CpG loci with significant inverse mRNA expression levels of their respective genes (27) , including PROM1/CD133, CD34 and SPP1. Cancer Cell Biology factors. To achieve this, the linear model calculates for any CpG locus whether its methylation level is correlated to any of the parameters, anatomical localization, size and mitotic counts, and whether a potential prognostic value of its methylation level is dependent or independent of those parameters. This linear model was applied to the methylation status of 1,505 CpG loci in 42 fresh-frozen GIST samples from the test set with clinical follow-up. According to the linear model, 25 CpG loci (22 genes) were associated with anatomical localization, three CpG loci (three genes) with genotype and 21 CpG loci (19 genes) with mitotic counts (Table 1 and Fig. 1b) . Furthermore, the linear model revealed that methylation patterns in the promoter regions of the two genes SPP1 and IFNG were significantly associated with tumor progression, independently of the clinicopathological parameters described above.
Genome-wide mRNA expression analysis identifies genes with significant inverse correlation between DNA methylation and mRNA expression
To determine if GIST-specific DNA methylation could contribute to distinct gene expression patterns, the levels of DNA methylation at 1.505 CpG dinucleotides were correlated to the mRNA expression levels of the respective genes using genome-wide mRNA expression data for a representative sample of 22 GIST specimens with highest RNA integrity. Given a limited number (807) of cancer-related genes that were interrogated for methylation analyses, this number of GIST samples sufficed for consistent conclusions. Thirty-one CpG loci corresponding to 27 genes were found to have a significant inverse correlation of DNA methylation and mRNA expression (Fig. 1c) . While PROM1/CD133, CD34 and SPP1 were among those genes with significant inverse correlation, IFNG was not. Bisulfite sequencing of a large portion of the promoter region of SPP1 in three representative GIST samples with low, intermediate and high SPP1 methylation levels according to the Illumina Golden Gate Methylation data set revealed strongest regulation of the non-CpG island CpG dinucleotide located 647 base pairs upstream of the transcription start site of SPP1 that was also represented on the array (Figs. 2a and 2d) . Pyrosequencing of this CpG site in all 76 fresh-frozen GIST samples confirmed the initial methylation levels of the Golden Gate Methylation data set ( Fig. 2e ; R 2 5 0.94). SPP1 mRNA expression was further examined by qRT-PCR in 51 of the 76 fresh-frozen GIST samples, revealing a significant inverse correlation between SPP1 DNA methylation determined by pyrosequencing and SPP1 mRNA expression determined by qRT-PCR (R 2 5 20.50).
SPP1 promoter hypomethylation is an independent prognosticator for shorter disease-free survival in GISTs
Using univariate Cox proportional hazard models, a significant correlation was established between hypomethylation of the non-island CpG site 647 base pairs upstream of the transcription start site of SPP1 and shorter disease-free survival. This significant correlation was observed both in the initial test set of fresh-frozen GIST samples with determination of methylation level using the Illumina Golden Gate method (p 5 0.002), and also in the validation set of paraffinembedded GIST samples with determination of methylation levels using pyrosequencing (p 5 0.006). Accordingly, univariate and multivariate Cox proportional hazard models comparing (i) anatomical localization, (ii) genotype, (iii) tumor size, (iv) mitotic counts and (v) SPP1 methylation level determined by pyrosequencing were performed for the whole cohort of 141 samples with clinical follow-up (Table 2 ). Notably, SPP1 methylation level remained as an independent prognostic parameter in the multivariate analysis (Table 2) . For Kaplan-Meier plot visualization of disease-free survival according to SPP1 methylation status, the GIST samples were grouped into three groups with low (<25%), intermediate (25-75%) and high (>75%) methylation levels of SPP1 (Fig.  3) , demonstrating the high correlation of this single methylation site with disease progression. On an individual basis, GISTs of the high-risk category were observed with high SPP1 methylation levels, which still had a favorable clinical outcome. For example, the highest methylation level (89.9%) was observed in a GIST from the small intestine with >10 mitoses/50 HPFs, which did not progress during a follow-up of 87 months followed by death of another cause. Regarding the only two GISTs among the intermediate-risk category that developed tumor progression, one had lowest methylation levels of only 4%, and the other one had intermediate methylation levels of 41%. Although only limited conclusion can be drawn from these individual cases, they support the independent prognostic role of SPP1 methylation levels observed for the whole study cohort.
SPP1 expression is correlated with its methylation level in vitro, and has stimulating effects on GIST signaling pathways
To evaluate whether the observed correlation between SPP1 methylation and expression levels could be reproduced also in vitro, we treated the GIST cell line GIST882 with different concentrations of the demethylating agent 5-aza-2 0 -deoxycytidine (decitabine) and quantified the mRNA and protein levels of SPP1. Decitabine treatment resulted in a decrease in SPP1 methylation accompanied by a dose-dependent increase of SPP1 mRNA expression after 72 hr of treatment (Figs. 4a and  4b ). Protein level of SPP1 was increased with the 10 nM decitabine concentration and stayed constant at 25 nM, potentially indicating saturation at protein level (Figs. 4c and 4d) . Furthermore, stimulation of GIST882 cells with 1 mg of recombinant SPP1 induced phosphorylation of ERK1/2 and, to a lesser extent, also of AKT, components of major oncogenic pathways downstream of SPP1 (Fig. 4e) . Overall, these in vitro data support our observations for both SPP1 epigenetic regulation and oncogenic importance of SPP1 modulation in GIST.
Discussion
We performed a targeted DNA methylation profiling analysis of GISTs, revealing distinct patterns according to anatomical localization, genotype and mitotic counts. Applying unsupervised machine learning techniques (PCA), GISTs were separated into three main subgroups: gastric with KIT mutation, gastric with PDGFRA mutation and small intestinal with KIT mutation. Notably, these three GIST subgroups are also characterized by different patterns of mRNA and miRNA expression, [7] [8] [9] [10] [11] 27 and have distinctive histomorphology and clinical behavior. [3] [4] [5] [6] Accordingly, the DNA methylation patterns identified in this study likely represent specific methylation signatures for these three GIST subgroups, which might impact the respective mRNA and miRNA expression patterns, as well as their clinical behavior. Notably, only three genes were differentially methylated in gastric GISTs with KIT vs. PDGFRA mutations. By contrast, extensive differences in DNA methylation signatures were demonstrated between KIT-mutated GISTs in the stomach vs. small intestine, with differential methylation at 25 CpG loci corresponding to 22 genes. This observation suggests that distinct patterns of epigenetic alterations may be involved in GISTs according to their anatomical origin. Among other genes, the hematopoietic stem cell antigen PROM1/CD133 was hypomethylated in gastric GISTs, which correlates to its upregulated expression. 28 Interestingly, rectal GISTs with KIT mutation clustered together with KIT-mutated GISTs from the stomach, consistent with a similar observation based on mRNA expression profiles. 7 This close relationship based on epigenetic and genetic features is in line with the findings that rectal GISTs are predominantly of spindle cell type and uniformly coexpress CD117 and CD34, similar to KIT-mutated gastric GISTs of the spindle cell type. 29 Correspondingly, two CpG dinucleotides located in the promoter region of CD34 showed a distinct methylation pattern among GISTs from different sites of the gastrointestinal tract, with low methylation levels among KIT-mutated GISTs from the stomach and rectum in contrast to high methylation levels in KIT-mutated GISTs from the small intestine. Notably, both PROM1/CD133 and CD34 were among the genes with a significant inverse correlation between DNA methylation and mRNA expression levels in this study. There is accumulating evidence that GISTs arise from ICCs or their stem cell precursor cells, and it has ).
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been shown that at least four different subpopulations of ICCs exist, which have a specific distribution in the gastrointestinal tract. 30 The distinctive DNA methylation patterns including CpG sites within the promoter regions of PROM1/ CD133 and CD34 that we report for GISTs from different sites of the gastrointestinal tract suggest that varying methylation profiles might underlie the gene expression differences reported for GISTs in these locations, and perhaps reflect the different origins of these GIST subgroups from different ICC-lineage subpopulations.
To identify novel and independent prognostic markers, a linear model comparing classical clinicopathological parameters and follow-up was used to identify CpG sites differentially methylated between GISTs with and without subsequent tumor progression independent of classical prognostic parameters. Additionally, genome-wide mRNA expression analyses were used to establish CpG loci with significant inverse correlation of DNA methylation and mRNA expression, focusing on non-CpG island CpG sites with probable impact on transcription factor binding when compared to probably more global patterns of DNA methylation deregulation frequently observed during tumor progression. This focused approach identified hypomethylation of a CpG dinucleotide 647 base pairs upstream of the transcription start site of SPP1 to be significantly associated with tumor progression, with inverse correlation to SPP1 mRNA expression. SPP1 is a chemokine-like, acidic glycoprotein that is secreted into the extracellular matrix and that binds certain CD44 variants (e.g., CD44v6) and integrin receptors (e.g., a v b 3 ).
31
SPP1 binding leads to the activation of major intracellular signaling regulators, including PI3K/AKT and RAS/MAPK, thereby effecting the oncogenic potential by promoting proliferation, survival, migration and angiogenesis. [32] [33] [34] Noteworthy, PI3K/AKT and RAS/MAPK are the main activated signaling pathways in GIST. 35, 36 Using an in vitro model, we observed that treatment of GIST882 cells with the demethylating drug decitabine resulted in a dose-dependent downregulation of SPP1 methylation that was accompanied by an upregulation of SPP1 mRNA as well as protein, supporting the relevance of epigenetic regulation on SPP1 expression in GISTs. Moreover, stimulation of GIST882 cells with SPP1 resulted in the activation of signaling intermediates ERK1/2 and, to a lesser extent, AKT. Altogether, these in vitro findings suggest that hypomethylation of SPP1 and the resulting increase in SPP1 expression may lead to an activation of downstream signaling components with potential impact on proliferation and invasion in GISTs. Notably, the independent prognostic impact of SPP1 methylation levels with respect to mitotic counts further highlights invasion as a potentially relevant but yet not well-understood mechanism of tumor progression in GIST.
SPP1 (osteopontin) has been demonstrated to be a prognostic marker on the protein level in different kinds of cancers [37] [38] [39] and also in GISTs. 40, 41 Comparing two different methods and two different GIST cohorts, we established and validated SPP1 methylation level as an excellent prognostic factor in GISTs. Using the whole cohort of 141 GISTs with long-term follow-up, SPP1 methylation level remained an independent prognostic factor in a multivariate analysis compared to anatomic localization, tumor size and mitotic counts. Notably, these three parameters are the best predictors of GIST behavior to date, and they are the basis for the currently used GIST risk classifications. 42, 43 Regarding the independent prognostic value of SPP1 in comparison to these clinicopathological parameters, we suggest that determination of SPP1 methylation might be especially valuable in GISTs of the intermediate-risk categories, for which the clinical behavior is currently unpredictable. In contrast to the already suggested prognostic role of semiquantitative evaluation of SPP1 protein levels, 40 ,41 the analysis of SPP1 methylation degree has the advantage to be a quantitative parameter, with highest sensitivity and reproducibility, and may be easier to implement into GIST risk classifications in the future. Given the fact that DNA analysis by pyrosequencing is now being routinely performed at many diagnostic molecular pathology laboratories, quantification of SPP1 methylation can be easily established at different laboratories, which is opposed to more complex molecular prognostication schemes that remain restricted to specialized laboratories. 44 
